RenewalBIO

Company Overview

Snapshot

Founded in June 2022, RenewalBIO operates with 11–50 employees. The company has secured funding across two rounds from four investors, with its most recent funding round occurring in May 2025.

Business overview

RenewalBIO is a Health Tech & Life Sciences company focused on addressing critical health issues such as organ and tissue shortages for transplantation, declining fertility, degenerative diseases, and aging. The company develops replacement cell therapies for human regenerative medicine and fertility, utilizing a novel approach that involves studying ex-vivo and ex-utero post-implantation embryoid models. RenewalBIO is also developing human patient-specific stem-cell derived embryoid models (SEM) grown in a controlled ex-utero device, aiming to optimize protocols for differentiating human iPSCs into mature cell types for transplantation, disease modeling, and drug studies.

Company Intelligence Q&A

When was RenewalBIO founded?

RenewalBIO was founded in June 2022.

What is RenewalBIO's primary focus in the Health Tech & Life Sciences sector?

RenewalBIO focuses on developing replacement cell therapies for human regenerative medicine and fertility, addressing issues like organ shortages, declining fertility, degenerative diseases, and aging.

How many employees does RenewalBIO currently have?

RenewalBIO currently has 11–50 employees.

Which investors participated in RenewalBIO's April 2023 funding round?

In April 2023, RenewalBIO secured funding from investors including Gaingels and NFX Capital.